Impaired fasting glucose and impaired glucose tolerance have distinct lipoprotein and apolipoprotein changes: The insulin resistance atherosclerosis study

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 4, 2013, Pages 1622-1630

  Lorenzo, Carlos ^a   Hartnett, Sara ^a   Hanley, Anthony J ^b   Rewers, Marian J ^c   Wagenknecht, Lynne E ^d   Karter, Andrew J ^e   Haffner, Steven M ^f  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e DIVISION OF RESEARCH   (United States)

^f Department of Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EPIDEMIOLOGICAL DATA; FEMALE; HUMAN; IMPAIRED FASTING GLUCOSE; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL;

ADULT; AGED; APOLIPOPROTEINS; ATHEROSCLEROSIS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FASTING; FEMALE; GLUCOSE INTOLERANCE; HUMANS; INSULIN RESISTANCE; LIPOPROTEINS; MALE; MIDDLE AGED; PREDIABETIC STATE;

EID: 84876244857     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3185     Document Type: Article

References (31)

1. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007; 30: 753-759.
2. DECODE study group Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999; 354: 617-621.
3. Stern MP, Fatehi P, Williams K, Haffner SM. Predicting future cardiovascular disease: do we need the oral glucose tolerance test? Diabetes Care. 2002; 25: 1851-1856.
4. Barr EL, Boyko EJ, Zimmet PZ, Wolfe R, Tonkin AM, Shaw JE. Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia. 2009; 52: 415-424.
5. de Vegt F, Dekker JM, Ruhe HG, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia. 1999; 42: 926-931.
6. Qiao Q, Dekker JM, de Vegt F, et al. Two prospective studies found that elevated 2-hr glucose predicted male mortality independent of fasting glucose and HbA1c. J Clin Epidemiol. 2004; 57: 590-596.
7. Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003; 52: 453-462.
8. Festa A, Williams K, Hanley AJ, et al. Nuclear magnetic resonance lipoprotein abnormalities in pre-diabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation. 2005; 111: 3465-3472.
9. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006; 29: 1130-1139.
10. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006; 26: 847-870.
11. Goff DC, D'Agostino RB Jr, Haffner SM, Otvos JD. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metabolism. 2005; 54: 264-270.
12. Kuller L, Arnold A, Tracy R, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 2002; 22: 1175-1180.
13. Arsenault BJ, Lemieux I, Després JP, et al. Comparison between gradient gel electrophoresis and nuclear magnetic resonance spectroscopy in estimating coronary heart disease risk associated with LDL and HDL particle size. Clin Chem. 2010; 56: 789-798.
14. Wagenknecht LE, Mayer EJ, Rewers M, et al. The Insulin Resistance Atherosclerosis Study (IRAS) objectives, design, and recruitment results. Ann Epidemiol. 1995; 5: 464-472.
15. Goff DC, D'Agostino RB, Haffner SM, Saad MF, Wagenknecht LE. Lipoprotein concentrations and carotid atherosclerosis by diabetes status: results from the Insulin Resistance Atherosclerosis Study. Diabetes Care. 2000; 23: 1006-1011.
16. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003; 26: 3160-3167.
17. Knudsen P, Eriksson J, Lahdenpera S, Kahri J, Groop L, Taskinen M-R. Changes of lipolytic enzymes cluster with insulin resistance syndrome. Diabetologia. 1995; 38: 48-53.
18. Chen Y-D, Facchini F, Landau C, Hollenbeck CB, Reaven GM. Plasma post-heparin lipoprotein lipase activity is decreased in normal individuals who are resistant to insulin-mediated glucose uptake. Endocrinol Metab. 1994; 1: 153-158.
19. Lahdenpera S, Syvanne M, Kahri J, Taskinen M-R. Regulation of low density particle size distribution in NIDDM and coronary disease: importance of serum triglycerides. Diabetologia. 1996; 39: 453-461.
20. Malmstrom R, Packard CJ, Caslake M, et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia. 1997; 40: 454-462.
21. Tilley-Kiesi M, Knudsen P, Groop L, Taskinen M-R. Hyperinsulinemia and insulin resistance are associated with multiple abnormalities of lipoprotein subclasses in glucose tolerant relatives of NIDDM patients. J Lipid Res. 1996; 37: 1569-1578.
22. Bavenholm PN, Pigon J, Ostenson CG, Efendic S. Insulin sensitivity of suppression of endogenous glucose production is the single most important determinant of glucose tolerance. Diabetes. 2001; 50: 1449-1454.
23. Adiels M, Taskinen MR, Packard C, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006; 49: 755-765.
24. Adiels M, Westerbacka J, Soro-Paavonen A, et al. Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia. 2007; 50: 2356-2365.
25. Corpeleijn E, Mensink M, Kooi ME, Roekaerts PM, Saris WH, Blaak EE. Impaired skeletal muscle substrate oxidation in glucoseintolerant men improves after weight loss. Obesity. 2008; 16: 1025-1032.
26. Boden G, Laakso M. Lipids and glucose in type 2 diabetes: what is the cause and effect? Diabetes Care. 2004; 27: 2253-2259.
27. Adiels M, Packard C, Caslake MJ, et al. A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. J Lipid Res. 2005; 46: 58-67.
28. Zhang YL, Hernandez-Ono A, Ko C, YasunagaK, Huang LS, Ginsberg HN. Regulation of hepatic apolipoprotein B-lipoprotein assembly and secretion by the availability of fatty acids. I. Differential response to the delivery of fatty acids via albumin or remnant-like emulsion particles. J Biol Chem. 2004; 279: 19362-19374.
29. Walldius G, Jungner I. Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy. Eur Heart J. 2005; 26: 210-212.
30. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009; 119: 931-939.
31. Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprote in Bvalues by use of International Reference Material. Clin Chem. 1994; 40: 586-592.